Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1

被引:69
作者
Santos, EA
Yoshida, CFT
Rolla, VC
Mendes, JM
Vieira, IF
Arabe, J
Gomes, SA
机构
[1] Fiocruz MS, Inst Oswaldo Cruz, Dept Virol, BR-21045900 Rio De Janeiro, Brazil
[2] Hosp Evandro Chagas, Inst Pesquisa, FIOCRUZ, BR-21004590 Rio De Janeiro, Brazil
[3] Fiocruz MS, Escola Nacl Saude Publ, CSEGSF, BR-21041210 Rio De Janeiro, Brazil
[4] Hosp Escola Sao Franscisco de Assis PAIPHA SAE, BR-20210030 Rio De Janeiro, Brazil
[5] Hosp Univ Gaffree & Guinle, BR-20270004 Rio De Janeiro, Brazil
关键词
D O I
10.1007/s10096-002-0868-0
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The presence of hepatitis B virus (HBV) serological markers was investigated in 170 patients (137 male, 33 female) infected with human immunodeficiency virus (HIV) type 1. Antibodies to the hepatitis B core antigen (anti-HBc antibodies) were detected in 115 (68%) patients. Of these 115, 14 (12%) were hepatitis B surface antigen (HBsAg) positive, 60 (52%) presented anti-HBs antibodies, and 41 (35%) were anti-HBc positive only. All 115 of the anti-HBc positive samples were tested for HBV DNA by using two polymerase chain reaction (PCR) assays that amplify the core and pre-S regions of the HBV genome, respectively. HBV DNA was detected in 23 samples: 7 of 14 (50%) HBsAg-positive samples, 12 of 60 (20%) anti-HBs-positive samples, and 4 of 41 (10%) samples positive for anti-HBc only. Six samples (all HBsAg positive) were positive in both PCR assays and 17 samples were HBV DNA positive in only one assay. The mean viral load in HBsAg-positive patients was higher than that observed in HBsAg-negative patients. A number of patients were receiving treatment with lamivudine, a drug that interferes with both HBV and HIV replication. However, neither the rate of HBV DNA positivity nor HBV load was significantly different between patients treated with lamivudine and those not treated with this drug.
引用
收藏
页码:92 / 98
页数:7
相关论文
共 50 条
[1]   ENHANCEMENT OF HBSAG DETECTION IN SERUM OF PATIENTS WITH CHRONIC LIVER-DISEASE FOLLOWING REMOVAL OF CIRCULATING IMMUNE-COMPLEXES [J].
ACKERMAN, Z ;
WANDS, JR ;
GAZITT, Y ;
BRECHOT, C ;
KEW, MC ;
SHOUVAL, D .
JOURNAL OF HEPATOLOGY, 1994, 20 (03) :398-404
[2]   Effects of lamivudine on replication of hepatitis B virus in HIV-infected men [J].
Benhamou, Y ;
Katlama, C ;
Lunel, F ;
Coutellier, A ;
Dohin, E ;
Hamm, N ;
Tubiana, R ;
Herson, S ;
Poynard, T ;
Opolon, P .
ANNALS OF INTERNAL MEDICINE, 1996, 125 (09) :705-+
[3]   EFFICACY OF LAMIVUDINE ON REPLICATION OF HEPATITIS-B VIRUS IN HIV-INFECTED PATIENTS [J].
BENHAMOU, Y ;
DOHIN, E ;
LUNELFABIANI, F ;
POYNARD, T ;
HURAUX, JM ;
KATLAMA, C ;
OPOLON, P ;
GENTILINI, M .
LANCET, 1995, 345 (8946) :396-397
[4]   Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine [J].
Bessesen, M ;
Ives, D ;
Condreay, L ;
Lawrence, S ;
Sherman, KE .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (05) :1032-1035
[5]   Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen:: Clinically significant or purely "occult"? [J].
Bréchot, C ;
Thiers, V ;
Kremsdorf, D ;
Nalpas, B ;
Pol, S ;
Paterlini-Bréchot, P .
HEPATOLOGY, 2001, 34 (01) :194-203
[6]   STATE OF HEPATITIS-B VIRUS-DNA IN HEPATOCYTES OF PATIENTS WITH HEPATITIS-B SURFACE ANTIGEN-POSITIVE AND ANTIGEN-NEGATIVE LIVER-DISEASES [J].
BRECHOT, C ;
HADCHOUEL, M ;
SCOTTO, J ;
FONCK, M ;
POTET, F ;
VYAS, GN ;
TIOLLAIS, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (06) :3906-3910
[7]   The clinical significance of surface antigen variants of hepatitis B virus [J].
Carman, WF .
JOURNAL OF VIRAL HEPATITIS, 1997, 4 :11-20
[8]   Occult hepatitis B virus infection: A hidden menace? [J].
Conjeevaram, H ;
Lok, AS .
HEPATOLOGY, 2001, 34 (01) :204-206
[9]  
COURSAGET P, 1991, FEMS MICROBIOL LETT, V83, P35
[10]   Nosocomial spread of hepatitis B virus in two hemodialysis units, investigated by restriction fragment length polymorphism analysis [J].
De Castro, L ;
Araujo, NM ;
Sabino, RR ;
Alvarenga, F ;
Yoshida, CFT ;
Gomes, SA .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2000, 19 (07) :531-537